These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29739251)

  • 1. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
    Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
    J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
    Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
    Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells.
    Zautner AE; Jahn B; Hammerschmidt E; Wutzler P; Schmidtke M
    J Virol; 2006 Jul; 80(13):6629-36. PubMed ID: 16775350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
    Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
    Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.
    Hazini A; Dieringer B; Klingel K; Pryshliak M; Geisler A; Kobelt D; Daberkow O; Kurreck J; Linthout SV; Fechner H
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coxsackievirus B3-Its Potential as an Oncolytic Virus.
    Geisler A; Hazini A; Heimann L; Kurreck J; Fechner H
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33919076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
    Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
    Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.
    Lin Y; Liu N; Yang C; Tan H; Fang C; Yu K; Zhao H; Xia N; Wang W; Huang X; Cheng T
    Virol J; 2024 Oct; 21(1):245. PubMed ID: 39369233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells - a Method to Personalize Virotherapy.
    Elsner L; Heimann L; Geisler A; Dieringer B; Knoch KP; Hinze L; Klingel K; Solimena M; Kurreck J; Fechner H
    Biol Proced Online; 2024 Apr; 26(1):11. PubMed ID: 38664647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
    Shafren DR; Williams DT; Barry RD
    J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
    Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
    Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
    Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
    Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
    J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and distribution of the receptors for coxsackievirus B3 during fetal development of the Balb/c mouse and of their brain cells in culture.
    Xu R; Crowell RL
    Virus Res; 1996 Dec; 46(1-2):157-70. PubMed ID: 9029788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
    Pinkert S; Kopp A; Brückner V; Fechner H; Beling A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.
    Girod M; Geisler A; Hinze L; Elsner L; Dieringer B; Beling A; Kurreck J; Fechner H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
    Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
    J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas.
    Hazini A; Dieringer B; Pryshliak M; Knoch KP; Heimann L; Tolksdorf B; Pappritz K; El-Shafeey M; Solimena M; Beling A; Kurreck J; Klingel K; Fechner H
    Hum Gene Ther; 2021 Feb; 32(3-4):216-230. PubMed ID: 33481658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.
    Tschöpe C; Müller I; Xia Y; Savvatis K; Pappritz K; Pinkert S; Lassner D; Heimesaat MM; Spillmann F; Miteva K; Bereswill S; Schultheiss HP; Fechner H; Pieske B; Kühl U; Van Linthout S
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.